TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intracardiac CrYoablation for AtrioVentricular Nodal Reentrant Tachycardia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Pre-Electrophysiology Study Inclusion Criteria:~* Supraventricular tachycardia (SVT) compatible with atrioventricular nodal reentrant tachycardia (AVNRT), documented by ECG, TTM, Holter or event monitor~Pre-Electrophysiology Study Exclusion Criteria:~* History of sustained (≥30 seconds) of ventricular tachycardia~* Atrial tachycardia or other arrhythmia that could be confused with AVNRT~* Reversible cause of SVT~* History of previous AVNRT ablation~* Therapy with amiodarone within last 90 days~* Unstable angina/myocardial infarction/open heart surgery in past 60 days~* New York Heart Association (NYHA) Classification III or IV currently or within the past 90 days~* Implantable cardiac rhythm device~* Atrioventricular block (first degree (PR interval ≥ 220ms), second degree, or third degree) or left bundle branch block~* Stroke or transient ischemic attack within the past 180 days~* Life expectancy less than 12 months~* Female known to be pregnant~* Unable/unwilling to give informed consent~* Unable/unwilling to comply with follow-up visits and study requirements~* Less than 18 years of age~* Active systemic infection~* Cryoglobulinemia~* Other conditions where the manipulation of the catheter would be unsafe (for example, intracardiac mural thrombus)~* Participating in a concurrent clinical study that may confound the results of this study~Post-Electrophysiology Study Inclusion Criteria:~* Subject must have one electrophysiology study documented inducible sustained (greater than or equal to 15 seconds) supraventricular tachycardia that is classified as AVNRT.~Post-Electrophysiology Study Exclusion Criteria:~* Presence of a second inducible arrhythmia that could be confused with AVNRT during follow-up or will likely result in ablation within the next 6 months~* Presence of inducible sustained ventricular tachycardia or fibrillation~* Presence of an accessory pathway~* Presence of abnormal conduction or refractoriness parameters of the atrioventricular conduction system.~* Indication for a pacemaker, defibrillator or cardiac resynchronization therapy (CRT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cryoablation (Type: EXPERIMENTAL): Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures.~2. Understands and agrees to comply with planned study procedures.~3. Male or non-pregnant female adult ≥18 years of age at time of enrollment.~4. Subject consents to randomization within 72 hours of hospital admission or transfer from another facility within 72 hours of index presentation.~5. Subjects with a positive COVID-19 diagnosis by nasal swab or serologic testing.~6. Hospitalized with a requirement for supplemental oxygen.~7. Have:~   * Either a D- Dimer \> 4.0 X ULN, OR~  * Sepsis-induced coagulopathy (SIC) score of ≥4~Exclusion Criteria:~1. Indications for therapeutic anticoagulation~2. Absolute contraindication to anticoagulation including:~   1. active bleeding,~  2. recent (within 1 month) history of bleed,~  3. dual (but not single) antiplatelet therapy,~  4. active gastrointestinal and intracranial cancer,~  5. a history of bronchiectasis or pulmonary cavitation,~  6. Hepatic failure with a baseline INR \> 1.5,~  7. CrCl \< 15ml/min,~  8. a platelet count \< 25,000,~  9. a history of heparin-induced thrombocytopenia (HIT) within the past 100 days or in the presence of circulating antibodies,~  10. contraindications to enoxaparin including a hypersensitivity to enoxaparin sodium, hypersensitivity to heparin or pork products, hypersensitivity to benzyl alcohol,~  11. pregnant female,~  12. inability to give or designate to give informed consent,~  13. participation in another blinded trial of investigational drug therapy for COVID-19

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Full Dose LMWH anticoagulation therapy (Type: EXPERIMENTAL): Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and \< 30ml/min) during the course of their hospitalization.
- Prophylactic/Intermediate Dose LMWH or UFH therapy (Type: ACTIVE_COMPARATOR): Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged 18 to 75 yrs of age presenting at a clinical site with symptoms diagnostic for an acute upper respiratory tract infection within the last 5 days~Exclusion Criteria:~* patients who had chronic, recurring respiratory signs and symptoms due to conditions such as chronic allergic rhinitis, chronic sinusitis or chronic bronchitis which in the investigator's opinion, confounded interpretation of symptom ratings for the acute upper respiratory infection. Also excluded were patients with a fever greater than 101 degrees F.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Mucinex D (Type: ACTIVE_COMPARATOR): Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given bid with a full glass of water for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Has a diagnosis of moderate to severe UC or CD documented in the medical chart.~2. Received at least one dose of vedolizumab or other biologic (infliximab, adalimumab, or golimumab \[UC only\]) during the eligibility period.~3. Received the biologic treatment as first-line or second line biologic for UC or CD.~4. Has a minimum of six months of follow-up between date of starting biologic therapy (index event) and the date of completion of the participant pre-selection registry.~Exclusion Criteria:~1. Received vedolizumab or another biologic as part of an interventional clinical trial ever in their lifetime (includes index treatment).~2. Index treatment was another biologic therapy other than vedolizumab, infliximab, adalimumab, or golimumab (UC only).~3. Initiated index treatment as combination therapy with two biologic agents.~4. The biologic was prescribed for treatment of perianal disease.~5. Received biologic therapy before the index period for a disease other than inflammatory bowel disease.~6. Medical chart is unavailable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Vedolizumab (Type: None): Participants diagnosed with UC or CD, who have initiated vedolizumab treatment between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index vedolizumab treatment initiation during the eligibility period, and then from date of index vedolizumab treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when vedolizumab treatment was initiated.
- Cohort 2: Other Biologic (Type: None): Participants diagnosed with UC or CD, who have initiated other biologic treatment (infliximab, adalimumab, or golimumab \[UC only\]) between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index other biologic treatment initiation during the eligibility period, and then from date of index other biologic treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when other biologic treatment was initiated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adult male (18 -70 yrs)~2. Body weight must be ≥ 50 kg and \< 120 kg, with a body mass index (BMI) \>18 but \< 35.~3. Laboratory parameters values within the normal range~Exclusion Criteria:~1. Contraindication or hypersensitivity to receiving nilotinib~2. Smokers or those who use of tobacco products or products containing nicotine~3. A past medical history of clinically significant Electrocardiogram abnormalities or a history/family history of long QT-interval syndrome.~4. History of fainting spells.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intra-Peritoneal Local Anaesthesia After Cytoreductive Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Patients with widespread malignant intra-abdominal ovary cancer stadium III-IV and are operated by extensive resection of intra-abdominal viscera as well as the parietal peritoneum (cytoreductive surgery, CRS)~Exclusion Criteria:~* Body mass index \> 35~* American Society of Anesthesiologists classification \> 3~* Renal dysfunction~* Allergic to acetylsalicylic acid~* Unwilling to provide informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Group R (Type: ACTIVE_COMPARATOR): Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
- Group P (Type: PLACEBO_COMPARATOR): Saline is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Saline would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age~* Capable of giving informed consents.~* Cases of NERD will be recruited on the basis of presence of heartburn and/or regurgitation using two validated GERD questionnaires in conjunction with an abnormal esophageal pH result and absence of erosions at standard endoscopy.~* Control subjects will include patients referred for an upper endoscopy for evaluation of non-reflux symptoms such as iron deficiency anemia, heme positive stools, screening of esophageal varices amongst others. A negative esophageal pH result and absence of erosions will be inclusion criteria for these patients.~Exclusion Criteria:~* Presence of macroscopic erosive esophagitis~* Pregnancy/lactation~* Chronic anticoagulation~* Patients with significant medical comorbidities (oxygen dependent chronic obstructive pulmonary disease, NYHA class III or IV congestive heart failure, recent diagnosis of cancer with a life-expectancy \< 5 years)~* History of Barrett's esophagus~* Presence of columnar lined distal esophagus on endoscopy with intestinal metaplasia~* Presence of cancer or mass lesion in the esophagus or stomach~* Esophageal strictures~* Peptic ulcer disease and Helicobacter pylori infection~* Prior history of esophageal surgery~* Allergic to PPIs~* Patients on drugs known to cause pill-related esophagitis (e.g. potassium supplements)~* Patients with HIV or other immunocompromised conditions who may have infectious esophagitis~* Eosinophilic esophagitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Esomeprazole (Type: ACTIVE_COMPARATOR): proton pump inhibitor
- Placebo (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Role of Chloroquine for Malaria Elimination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male individuals~* P. falciparum infection detected by microscopy (Minimum 250 parasites/microliter; Maximum 10.000parasites/microliter)~* Ability to swallow oral medication~* Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and~* Informed consent from the participant individual~Exclusion Criteria:~* Age \<18 years~* Female individuals~* Axillary temperature \>=37.5ºC~* Presence of any other co-existing clinical condition that in the opinion of the recruiting physician would not allow the individual to be considered a healthy asymptomatic carrier~* Regular medication which may interfere with antimalarial efficacy or antimalarial pharmacokinetics, such as Cotrimoxazole~* History of hypersensitivity reactions or contraindications to CQ~* Known HIV positive patients in treatment with antiretrovirals

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chloroquine (Type: EXPERIMENTAL): Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Children's Healthy Living Community Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Community criteria~Four (4) to six (6) communities in each of five (5) jurisdictions (Alaska, American Samoa, Commonwealth of Northern Mariana Islands, Guam \& Hawai'i) chosen for community randomized program based on:~* 2000 U.S. Census criteria~  * \>1000 people~ * \>25% Native population,~ * \>10% under 5y~* CHL Staff Community Evaluation~  * Sufficient Head Start/preschool, kindergarten~ * Children live \& go to school in area~ * Separation between communities to allow testing~ * Access for CHL~ * Sufficient community cohesiveness~ * Sufficient settings for program (community centers, parks, stores...)~* Child criteria • 2-10 years of age~Exclusion Criteria:~* Child criteria~  * Known orthopedic, psychological or neurologic impairments that prevent physical activity~ * Presence or history of any metabolic or chronic health problems known to affect intermediary metabolism (e.g. untreated thyroid disease, cancer, hepatic disease, renal disease, diabetes, cardiovascular disease, hypertension)~ * Irregular use of prescription or over-the-counter medications known to affect appetite, food intake or intermediary metabolism (e.g. appetite suppressants, lithium, antidepressants, etc.)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 8 Years
- Healthy Volunteers: t

Study Arms:
- CHL program (Type: EXPERIMENTAL): Multiple component environmentally focused intervention designed with a community engagement process.
- Delayed Optimized CHL program (Type: OTHER): Comparison community that participated in community engagement process and received delayed optimized program.
- Temporal (Type: NO_INTERVENTION): Communities assessed for temporal trends in anthropometry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 25 and 65 years~2. Understanding of the German language~3. Understanding the procedures and the risks associated with the study~4. Participants must be willing to adhere to the protocol and sign the consent form~5. Participants must be willing to refrain from taking illicit psychoactive substances during the study~6. Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session, as well as during the study day.~7. Participants must be willing not to drive a traffic vehicle within 48 h following LSD administration.~8. Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session.~Exclusion Criteria:~1. Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>150/95 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder.~2. Current or previous psychotic or major affective disorder~3. Psychotic or major affective disorder in first-degree relatives~4. Relevant prior illicit drug use (except tetrahydrocannabinol (THC)-containing products) more than 10 times or any time within the previous 2 months.~5. Pregnant or nursing women.~6. Participation in another clinical trial (currently or within the last 30 days)~7. Use of medications that may interfere with the effects of the study medications (any psychiatric medications)~8. Insufficient interpersonal relationship/rapport with study physician as judged by the study physician

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo, LSD (Type: OTHER): Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete